# drug pricing guide

Drug pricing & reimbursement in Saudi Arabia.

How the SFDA sets a medicine's price — a value-based decision benchmarked against a basket of reference countries — why that price only erodes over the lifecycle (the −25% generic and −20% biosimilar cuts, the 30% re-pricing cap, the two-year rule), and how a price turns into reimbursement through NUPCO and the Council of Health Insurance — now underpinned by a mandatory health-economic dossier.

Last updated 26 June 2026For BD, market-access & regulatory teams · not legal or tax advice
Rules are quoted; a few figures need verifying

The pricing rules here — the generic ladder (70 / 65 / 60%), the −25% innovator and −20% biosimilar cuts, the 30% re-pricing cap and the two-year rule — are quoted directly from the primary SFDA Pricing Rules (DS-REQ-082-V03), and the mandatory economic-evaluation dossier (since 1 July 2025) from the official SFDA EES guideline. But three things genuinely move or are not in a single primary doc: the exact list of reference countries (SFDA may revise it; public lists disagree), the SAR fee amounts (not published in the Rules), and the NUPCO / CHI reimbursement mechanics. Those carry a to verify marker. Confirm them with SFDA, NUPCO or CHI before acting. This guide is not legal or tax advice.

Who pricesSFDACore methodValue + reference pricePrice typeMax ceiling price1st generic cut−25% innovatorRe-pricing cap≤30% per cutHTA dossierMandatory · Jul 2025
How to read the markers:S#HIGH — read off a primary official source (the SFDA Pricing Rules or EES guideline), with its citation.to verifyTo verify — described by an official body page or advisory, not pinned to a single primary statute.
# the pricing pathway

From price file to a published ceiling

The SFDA Pricing Committee sets the price of every medicine before it reaches the market. Steps marked gate are the ones that actually decide the number — the mandatory economic-evaluation dossier and the price decision itself.

Process steps
Submit the price file (with the Price Certificate)

The company files a pricing application with a recent Price Certificate (Form 16) carrying the ex-factory price, the wholesale price in the country of origin, and the ex-factory/export prices in every country where the product is marketed. The certificate must be ≤6 months old at the time of pricing.

S1, Art. 2
Pay the fees (SADAD)

Financial fees are paid upon approval to submit the application, settled through a SADAD invoice (Saudi Arabia's national bill-payment system). The Rules set out the process; they do not publish the SAR fee amount.

S1, Art. 26
Economic Evaluation Study (HTA) — now mandatorygate

Since 1 July 2025 an Economic Evaluation Study (a health-economic / HTA dossier — e.g. a cost-utility analysis) is mandatory for products undergoing registration, re-evaluation or renewal. The published cost-effectiveness threshold is SAR 50,000–75,000 per QALY (quality-adjusted life year).

S2
Reference-price benchmarking

The Pricing Committee benchmarks the proposed price against the same product's prices in SFDA's basket of reference countries, alongside the prices of therapeutic alternatives already registered in the Kingdom. SFDA may revise the reference-country list periodically.

S1, Art. 2–3
Price decision (a ceiling price)gate

The Committee sets the price weighing added therapeutic value, registered alternatives, pharmacoeconomics, and the reference/origin prices. The figure it sets is a MAXIMUM price — the company may sell lower, but not higher.

S1, Art. 2 · 23
Price implemented & published

The approved price is applied and published per SFDA's price-implementation procedure, and the product can be marketed at (or below) that ceiling.

S4
Appeal window (60 days)

The company or its agent may appeal the price within 60 days of being notified of the new price. (No appeal is allowed for the optional pre-registration pricing service.)

S1, Art. 25
How the price is set
Added therapeutic value of the productWhat clinical benefit it adds over what is already available.S1, Art. 2(1)
Prices of therapeutic alternatives already registered in the KingdomAn internal-reference check — a new product should not simply out-price its registered equivalents.S1, Art. 2(2)
Pharmacoeconomic / economic-evaluation studiesNow the mandatory EES dossier — value for money against the SAR 50,000–75,000 / QALY threshold.S1, Art. 2(3) · S2
Ex-factory & wholesale price in the country of originThe manufacturer's home-market price, supplied on the Price Certificate.S1, Art. 2(4–5)
Ex-factory / export prices in all countries where it is marketedThe external-reference (ERP) input — the same product's prices abroad.S1, Art. 2(7–8)
The price in the approved reference-price basketSFDA's defined basket of reference countries (the list sits in the Price Certificate Form and SFDA may revise it).S1, Art. 2(9)

The figure the Committee approves is a maximum (ceiling) price — a company may sell below it but not above it S1, Art. 23. There is no single published formula (lowest vs average reference price); the Rules describe a value-plus-reference judgement, so the exact reference mechanic is to verify against SFDA.

# price over the lifecycle

Why the price only goes one way: down

The price you defend at launch is the price you erode from. The Rules hard-wire the erosion: the innovator is cut the moment a follower registers, and each generic is capped lower than the last. The bars below index every ceiling to the launch price (= 100%).

Innovator at launch100% (ceiling) S1, Art. 23
Innovator after 1st generic−25% S1, Art. 4
1st generic≤70% S1, Art. 5A
2nd generic≤65% S1, Art. 5B
3rd generic onward≤60% S1, Art. 5C

Read the cuts as rules, not estimates: the innovator drops 25% when the first generic registers S1, Art. 4, and generics are capped at 70% / 65% / 60% of the pre-cut innovator price by entry order S1, Art. 5. Being the first generic is worth roughly ten points of ceiling over being the third.

Biologic trackPrice ceilingThe ruleSource
Biologic after 1st biosimilar−20%Reference biologic cut by 20% when the first biosimilar registers.S1, Art. 6
1st biosimilar≤75%First biosimilar priced at ≤75% of the pre-cut biologic price.S1, Art. 7A

Biologics follow a parallel, gentler ladder: the reference biologic is cut 20% on first-biosimilar entry, and the first biosimilar is capped at 75% S1, Art. 6 · 7 — versus the steeper −25% / 70% small-molecule path.

# after launch

Re-pricing: the levers that move a live price

A Saudi price is never finally settled. The Committee can re-evaluate it through the product's life — but the Rules also bound how fast and how far a price can fall, which is what makes erosion forecastable.

A single cut is capped at 30%Re-pricing must not reduce a product's price by more than 30% at a time.S1, Art. 9
Therapeutic-class review can trigger a cutSFDA may re-evaluate a price when it reviews the prices of products in the same therapeutic class.S1, Art. 11A
A price drop abroad flows throughA reduction in the country of origin or other marketed countries can trigger a Saudi re-evaluation.S1, Art. 11B
Expensive / outcomes-based products can be reviewed earlyWithin the first two years for expensive products and products that must prove their health outcomes.S1, Art. 10
A two-year floor between cutsA price will not be reduced within two years of the last approved reduction — a hard cool-off.S1, Art. 22
Low-price products are spared on renewalProducts whose packs and strengths are all under SAR 30 are exempt from re-pricing at renewal.S1, Art. 12A

The two guard-rails that matter for planning: any single cut is capped at 30% S1, Art. 9, and no price can be cut again within two years of its last reduction S1, Art. 22 — a hard cool-off that turns re-pricing into a schedulable event rather than a continuous risk.

# getting paid

From an approved price to reimbursement

A price is permission to sell, not a guarantee of revenue. In Saudi Arabia the public side runs through one central buyer (NUPCO) and the private side through one insurance formulary (CHI) — and a health-economic case now sits underneath both. The list below is the practical access chain; the public/private mechanics are advisory-described, so they carry a verify marker.

SFDA registration + an approved priceA marketing authorization and a Committee-set ceiling price are the entry ticket to every downstream channel.S1 · S3
Economic Evaluation Study on fileMandatory since 1 July 2025 for registration, re-evaluation and renewal — the value case the payer side now expects.S2
Public channel — NUPCO procurement (the de-facto public reimbursement)NUPCO is the exclusive central buyer for MOH and government health entities; winning its unified tenders / framework agreements is how a priced drug actually reaches public-sector patients.to verify
Private channel — CHI Insurance Drug FormularyFor the mandatory private-insurance market, the Council of Health Insurance maintains the Insurance Drug Formulary that standardizes what insurers cover.to verify
HTA review feeds reimbursement decisionsAn emerging central HTA capability (under the MOH/Vision-2030 value-based shift) uses the EES evidence; advisory sources put a single HTA review at roughly 60–90 days, often in parallel with regulatory review.to verify
# the structural shift

From price-taker to value: the HTA mandate

The biggest change to KSA pricing in years: as of 1 July 2025, an economic-evaluation (HTA) dossier is mandatory — the system is moving from pure reference pricing toward value-based pricing, in line with Vision 2030.

EES guideline publishedofficial10 Jul 2024 S2
EES mandatory for pricing, re-evaluation & renewalbinding1 Jul 2025 S2
Cost-effectiveness threshold (per QALY)guide valueSAR 50,000–75,000 S2
Indicative HTA review windowadvisory~60–90 days to verify

The mandate and the SAR 50,000–75,000 / QALY threshold are stated in the official SFDA EES guideline (v1.1) S2; the guideline calls the threshold “estimated” with case-by-case flexibility, so treat it as a guide value, not a hard cutoff. The review-window timing is advisory-sourced to verify and the central HTA body is still maturing.

# the call

Where is your price decided?

The pricing playbook splits cleanly by product type: an innovator defends a value-set ceiling against erosion; a follower captures a mechanical ceiling and then competes on volume.

What's the strongest lever on your Saudi price — and how exposed are you to erosion?
PROTECT → value & lifecycle
An innovator / on-patent product
Your launch ceiling is set on therapeutic value, your reference-country prices and (now) your economic-evaluation case. The risk is downstream erosion: a single generic or biosimilar triggers an automatic cut.
  • Build the EES / value dossier before pricing — it is mandatory and it anchors the ceiling
  • Manage your international price corridor — low reference-market prices pull the Saudi price down
  • Model the −25% (generic) / −20% (biologic) step the day the first follower registers
The price you defend at launch is the price you erode from.
CAPTURE → ladder & tenders
A generic / biosimilar follower
Your ceiling is mechanical — 70% / 65% / 60% by entry order (generics) or ≤75% (first biosimilar). Past that, the contest is volume: the public win runs through NUPCO tenders, not a higher list price.
  • Entry order sets your ceiling — being first generic (≤70%) beats being third (≤60%)
  • The list price is a ceiling; competition and tenders decide the realized price
  • NUPCO procurement is where public-sector volume is won or lost
After the ladder, price is a tender game, not a list-price game.
Verify before relying on these

Most of this guide is quoted directly from primary SFDA regulation. These are the few items that are not pinned to a single primary document — the things to confirm with SFDA, NUPCO or CHI before treating them as final.

Reference-country basket
  • The actual LIST of reference (basket) countries is NOT fixed in the Pricing Rules — Art. 2 keeps it in the Price Certificate Form and says SFDA 'may review the list of reference countries periodically'. Public advisory lists DISAGREE (a ~15–16-country list vs an expanded ~21-country list incl. GCC/MENA peers). We therefore do not assert a specific country list here — confirm the current basket directly with SFDA.
  • Whether the benchmark uses the lowest, the average, or a weighted reference price is not stated as a single rule in DS-REQ-082; the Rules describe a value-plus-reference judgement by the Committee, not a fixed formula. Do not present a single mechanical reference rule as fact.
Fees & amounts
  • The SAR fee amounts for pricing / pre-pricing / re-pricing are NOT published in the primary Rules (the process and the SADAD step are). Any specific SAR pricing-fee figure seen elsewhere is consultancy-sourced — verify before quoting.
  • The cost-effectiveness threshold (SAR 50,000–75,000 / QALY) is stated in the official EES guideline (S2) as an 'estimated' threshold with case-by-case flexibility — treat it as a guide value, not a hard cutoff.
Reimbursement plumbing
  • NUPCO-as-public-reimbursement and the CHI Insurance Drug Formulary mechanics are described by official body pages (S5/S6) and advisories (S9) rather than a single reimbursement statute — confirm current tender, formulary and co-payment specifics with NUPCO / CHI directly.
  • The central HTA body, its remit and the ~60–90-day review window are emerging and advisory-sourced (S9/S10); verify the current institutional setup before relying on timings.
# why this matters for your team

The RaqibHealth angle

Pricing and reimbursement sit downstream of the SFDA register — the events that move a Saudi price (a generic entry, a loss-of-exclusivity, a new competitor) surface first as register activity that RaqibHealth tracks.

Pricing and reimbursement in KSA are downstream of the SFDA register — the generic/biosimilar entry that triggers a −25% / −20% cut shows up first as a new SFDA approval. RaqibHealth watches that register so the price event isn't a surprise.
Loss-of-exclusivity timing drives the erosion clock; RaqibHealth's PatentCliff radar maps the LOE windows that precede the mandatory innovator price cut.
The mandatory Economic Evaluation Study (since 1 Jul 2025) makes the value case central — a KSA-specific intelligence layer on alternatives, registrations and the competitive set strengthens that dossier.
Reminder on scope: pricing, NUPCO tendering and CHI formulary decisions are made by SFDA, NUPCO and CHI — RaqibHealth is market intelligence, not a pricing, legal or tax adviser. Confirm every figure against the primary source before acting.
# sources & provenance

Where every figure comes from

Official SFDA / government sources are marked in green. The pricing rules, ladders, caps and the two-year rule are quoted from the primary SFDA Pricing Rules (S1); the mandatory economic-evaluation dossier and the QALY threshold are from the official SFDA EES guideline (S2). NUPCO / CHI body pages and reputable advisories corroborate the reimbursement chain.

This guide is informational and not legal, regulatory or tax advice. Saudi pricing and reimbursement rules change — the SFDA reference-country basket, fee amounts, the economic-evaluation requirements and the NUPCO / CHI reimbursement pathways are all subject to revision — so always confirm against the SFDA, NUPCO and CHI primary sources before acting. RaqibHealth cites its sources on every record. info@raqibhealth.com · RaqibHealth home

Get intelligence like this — live

The weekly SFDA brief — free

What changed in the Saudi market this week — new approvals, recalls and opportunity windows — in one Monday email. Or start a free trial for the full platform.

Start a free trial → · the full SFDA-intelligence platform